Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Internet Explorer is no longer a supported browser.

This website may not display properly with Internet Explorer. For the best experience, please use a more recent browser such as the latest versions of Google Chrome, Microsoft Edge, and/or Mozilla Firefox. Thank you.

COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC. Get the latest research information from NIH.

Your Environment. Your Health.

Dataset Details

Superfund Research Program

Title: Intestinally-biased FXR agonism browns white adipose tissue preventing obesity and insulin resistance

Accession Number: SRP048631

Link to Dataset: https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP048631

Repository: Sequence Read Archive (SRA)

Data Type(s): Nucleotide Sequence

Experiment Type(s): Transcriptome analysis

Organism(s): Mus musculus

Summary: The distributed expression of bile acid (BA) sensor Farnesoid X receptor (FXR) has led to new therapies targeting cholesterol metabolism, triglyceride production, hepatic steatosis and biliary cholestasis. In contrast to the effects of system-wide drugs, we posited that selective activation of intestinal FXR might mimic the restricted bile acid response linked to feeding. Like systemic drugs, the gut-specific FXR agonist Fexaramine robustly induces enteric FGF15 leading to alterations in BA composition but does so without activating FXR target genes in the liver. Unlike systemic drugs, we find Fexaramine reduces diet-induced weight gain, body-wide inflammation and hepatic glucose production, while enhancing thermogenesis and browning of white adipose tissue. These pronounced metabolic improvements suggest tissue-restricted FXR activation as a new approach in the treatment of obesity and metabolic syndrome.

Publication(s) associated with this dataset:
  • Fang S, Suh J, Reilly SM, Yu E, Osborn O, Lackey D, Yoshihara E, Perino A, Jacinto S, Lukasheva Y, Atkins AR, Khvat A, Schnabl B, Yu RT, Brenner DA, Coulter S, Liddle C, Schoonjans K, Olefsky J, Saltiel AR, Downes M, Evans RM. 2015. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med 21(2):159-165. doi:10.1038/nm.3760 PMID:25559344 PMCID:PMC4320010
Project(s) associated with this dataset:
Back
to Top